Searched for
ABBVIE LICENSING DEAL
Indian pharma may take AI pill to cut time and costs in drug R&DIndian pharmaceutical giants Sun Pharma and Glenmark are embracing Artificial Intelligence to speed up new drug creation. This technology p...- Glenmark shares gain 2% as firm receives $700 million upfront payment from AbbVie dealGlenmark Pharmaceuticals' shares surged following its subsidiary's $700 million upfront payment from AbbVie for an exclusive licensing agre...
- Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&PS&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing agreement with AbbVi...
- Glenmark surges 20% after major drug licensing deal with AbbVieGlenmark Pharmaceuticals shares surged following a significant licensing agreement. Ichnos Glenmark Innovation partnered with AbbVie for a ...
- Glenmark Pharma shares rally 14% on AbbVie boost; analysts hike targets to Rs 2,800Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001...
- Glenmark Pharmaceuticals shares rally up to 20%, mutual funds lead the charge over retail investorsThe shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day’s high of Rs 2,286 following a landmark $2 billion licensing...
- Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation playGlenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“va...
- Stocks in news: DMart, IREDA, TCS, ZEE, HUL, Glenmark PharmaMarkets declined on weekly expiry day, with several companies in focus due to earnings and news. TCS reported a 6% profit increase, while I...
- Glenmark, AbbVie ink $700 million drug licensing dealGlenmark Pharmaceuticals has entered into a significant agreement with AbbVie to commercialize its investigational drug, ISB 2001, targetin...
- China’s biotech is redrawing the global pharma map; what India can learnAmerican biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. Astr...
- Will the 2021 earnings bonanza really happen?According to Bloomberg Intelligence, analysts expect a whopping 23.2% increase in earnings per share among S&P 500 companies, up from 22.3%...
- Lupin developing new products to treat cancer, other diseasesSharing details, Kamboj said the the Mumbai-based company is currently working on developing various products, including two major ones to ...
- Decoding the impact of Ilumya, Sun Pharma's first biologic drug approved by the US FDALast year Sun Pharma signed another deal with South Korea's Samsung Biologics to get the drug manufactured on approval.
- Tildra approval to give sentimental push to Sun PharmaThe drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...
- Abbott to set up innovation hub in IndiaAbbott has its existing innovation and development centres in Chile and Columbia for the regional needs in Latin America and one in Russia.
Load More
